Source: Conotoxins and Prialt Sources
source confidence: Medium status: Draft updated 2026-06-18
Summary
The 2004 FDA label describes Prialt's composition, indication, delivery route, warnings, and clinical-trial basis. This page represents that single government record, not the broader discovery history.
Useful Claims
- Prialt contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in Conus magus.
- The drug is administered intrathecally and indicated for management of severe chronic pain in patients who warrant intrathecal therapy and are refractory to or intolerant of other treatment.
- FDA labeling emphasizes serious psychiatric and neurological risks.
Reliability Notes
The FDA label is authoritative for the approved drug, indication, warnings, and clinical description at approval. It does not establish the discovery, patent, licensing, or University of Utah institutional story; those require separate evidence artifacts.